Can a Two-Drug combo outsmart resistant colorectal cancer?
NCT ID NCT06221423
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This trial is testing whether combining two standard drugs—fruquintinib and TAS-102—can help people with metastatic colorectal cancer that has stopped responding to at least two prior chemotherapy regimens. The study will measure how long patients live without the disease getting worse and overall survival. Participants are adults aged 18 to 75 with confirmed metastatic colorectal cancer who are eligible for salvage treatment with fruquintinib.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fruquintinib combined with TAS-102 (trifluridine/tipiracil)
- What this could lead to
- If the combination works, it could offer a new treatment option to extend survival for people with advanced colorectal cancer who have run out of standard options.
- What could go wrong
- This is an early, single-center study with no results yet. The combination may not improve outcomes and could increase side effects compared to either drug alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?